Replimune Group, Inc. (REPL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$14.45-2.17%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Manage operating losses and cash burn: metric not reported.
Replimune aims to resubmit its cancer drug RP1 to the FDA soon. The company is cutting losses, improving cash burn from negative $77M to negative $65.9M. A new strategic partnership supports RP1's development. Positive FDA feedback could unlock value.
Replimune has missed earnings repeatedly and lost FDA approval twice. It still loses over $70M quarterly and has no revenue yet. The drug approval and commercial success remain uncertain. Cash burn and losses may continue.
The market has no clear consensus revenue or earnings growth priced in. Estimates show continued losses and minimal revenue through 2027. Our view is cautious given regulatory and financial risks.
Breaks if: BLA resubmission delayed beyond 2026-Q3
Breaks if: Operating loss worsens beyond negative $71.9M by 2026-Q3
No partnership progress or deal termination by 2026-Q4
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is in a high-risk sector, specifically healthcare, where REPL is currently loss-making. The thesis is weakened due to recent financial performance and mixed execution on management priorities.
The market seems to have a low expectation of fragility, as no fragility gates have fired. However, the recent shift in performance from robust to fragile indicates that the current valuation may not fully reflect the risks involved.
Management is focused on launching TUDRIQEV and advancing clinical trials, but the execution has been mixed. The near-term risk of missing expectations is low, but the industry has seen peers miss recently, which could impact REPL.
The long-term outlook depends on the successful launch of TUDRIQEV and the outcomes of ongoing clinical trials. Additionally, the performance of sector bellwethers and overall economic conditions will play a significant role in shaping REPL's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The reason to own REPL has diminished due to recent financial performance. It fell from the robust half to the weak half of its sector. However, the company gained FDA approval for an advanced melanoma treatment, which supports its regulatory objectives.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, REPL's performance will be closely tied to its execution on key priorities and broader market conditions. Not investment advice.